Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of maduramicin ammonium in preparation of anti-breast cancer drugs

A kind of madomecin ammonium and anti-breast cancer technology, which is applied in the field of medicine, and can solve the problems such as no reports on the cytotoxic effect of madomecin ammonium on breast cancer

Pending Publication Date: 2021-12-31
NANJING AGRICULTURAL UNIVERSITY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although some studies have preliminarily analyzed the toxic mechanism of maduramicin ammonium on mammalian cells, there is no report on the toxic effect of maduramicin ammonium on breast cancer cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of maduramicin ammonium in preparation of anti-breast cancer drugs
  • Application of maduramicin ammonium in preparation of anti-breast cancer drugs
  • Application of maduramicin ammonium in preparation of anti-breast cancer drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] According to the method in cell passage, six kinds of cells, MCF-10A, EpH4-Ev, MDA-MB-231, 4T1, CMT-U27 and canine primary breast cancer cells, were digested with trypsin respectively, and the above cells were divided into 5000 Cells / well were inoculated into 96-well cell culture plates, 100 μL per well, and cultured in a 37°C cell culture incubator. When the cells in each well grew to about 80%, the cells were treated with different concentrations (0μM, 0.0625μM, 0.0125μM, 0.25μM, 0.5μM, 1μM) of amdomicin ammonium for 24h, 48h, and 72h respectively, and 6 parallel replicates were designed for each group. hole, placed in CO 2 Continue culturing at 37°C in an incubator. After 24h, 48h, and 72h, 10 μL of CCK-8 solution was added to each well, and the incubation was continued for 1 hour in the incubator. The OD value at a wavelength of 450 nm was measured with a microplate reader.

[0036] The result is as figure 1 Shown: different concentrations of maduramicin ammoniu...

Embodiment 2

[0038] Select well-growing MDA-MB-231 cells and 4T1 cells, digest and centrifuge for passage, and when the cells grow to about 80% of the bottom of the culture dish, discard the original culture medium, and add different concentrations (0μM, 0.0625μM, 0.125μM, 0.25 μM, 0.5μM, 1μM) maduramicin ammonium sterile culture solution 10mL, continue to place in 5% CO 2routinely cultured in a cell culture incubator. Three time points of 24h, 48h, and 72h after administration were selected, and the cells were observed under a microscope and photographed.

[0039] The results show that: if figure 2 , 3 As shown, MDA-MB-231 cells and 4T1 cells were treated with different concentrations of maduramicin ammonium (0-1μM) for 24h, 48h and 72h respectively. With the increase of drug concentration and action time, the growth of breast cancer cells was inhibited. The activity gradually decreased, and at the same time, the cells gradually became round and shrunk, fell off from the culture dish ...

Embodiment 3

[0041] Digest well-grown MDA-MB-231 cells and 4T1 cells and inoculate 1×10 cells per well in a six-well plate 5 per cell to distribute the cells evenly across the plate. Place the culture plate in a 37°C cell culture incubator. On the next day, the original culture medium was discarded, and 2 mL of maduramicin ammonium sterile culture medium containing different concentrations (0 μM, 0.0625 μM, 0.25 μM, 1 μM) was added to each well, and the routine culture was continued in the cell culture incubator. After 48 hours of drug action on the cells, digest the cells with trypsin digestion solution (excluding EDTA), pipette into a cell suspension, transfer it to a 5mL centrifuge tube, place it in a centrifuge at 2000r / min for 5min, and then add pre-cooled PBS to wash the cell pellet Twice, collect 1-5×10 5 Add 500 μL of pre-cooled binding buffer to resuspend the cells, add 5 μL Annexin V-FITC and mix well, then add 5 μL propidium podide, mix well, and react for 15 minutes at room t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biomedical treatment, and discloses an application of maduramicin ammonium in preparation of an anti-breast cancer drugs. The application range of maduramicin ammonium is expanded, support is provided for preparation of maduramicin ammonium in anti-breast cancer drugs, and an effective tool is provided for clinical application of maduramicin ammonium in treatment of breast cancer. Tests show that the maduramicin ammonium has the in-vitro proliferation activity of inhibiting human breast cancer MDA-MB-231 and 4T1 cells, dog breast cancer CMT-U27 cells and clinically derived dog primary breast cancer cells within a certain concentration range, and the maduramicin ammonium can induce in-vitro apoptosis of the breast cancer cells. The maduramicin ammonium can significantly inhibit the growth of 4T1 inoculated mouse in-situ breast cancer. Therefore, maduramicin ammonium can be used for preparing anti-breast cancer drugs, especially for treating triple negative breast cancer.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of maduramicin ammonium in the preparation of anti-breast cancer drugs. Background technique [0002] Breast cancer is one of the most common malignant tumors that endanger the health of women and female animals. In triple-negative breast cancer, since the expressions of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 are all negative, tumor cells can easily spread to the lung, liver and central nervous system. In recent years, with the continuous in-depth analysis of the occurrence and development mechanisms of various cancers, targeted therapy drugs with unique mechanisms of action have been continuously discovered. Therefore, mining anti-triple-negative breast cancer drugs with high efficiency and low toxicity from existing drug resources has theoretical significance and practical value. [0003] In recent years, some polyether io...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P35/00A61P35/04
CPCA61K31/7048A61P35/00A61P35/04
Inventor 高修歌宋昕昊张静静季辉彭麟郭大伟江善祥
Owner NANJING AGRICULTURAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com